A new clinical trial has recently begun for a promising but complex type of cancer treatment called BPX-601, designed specifically for men dealing with advanced prostate cancer that has stopped responding to traditional therapies. This therapy is a form of CAR T-cell treatment, which means doctors take a patient’s own immune cells, reprogram them in […]
A novel double-masked T-cell engager targeting prostate-specific membrane antigen (PSMA), called JANX014, has entered phase 1 testing in patients with metastatic castration-resistant prostate cancer (mCRPC). The first-in-human, open-label, multicenter trial, which dosed its initial participant in mid-April 2026, evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and early antitumor activity through ascending intravenous doses administered as monotherapy to […]
PTT‑4256 is an emerging first‑in‑class small‑molecule inhibitor of GPR65, a proton‑sensing G‑protein‑coupled receptor selectively expressed on immune cells within the acidic tumour microenvironment. It is being evaluated in the RAISIC‑1 trial, a modular, open‑label, phase 1/2 study in patients with advanced solid tumours designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy. The trial’s […]
Bispecific T cell engagers, while conceptually powerful, have carried a toxicity profile that constrains their clinical utility. AZD8359, a novel trispecific T cell engager now entering its first-in-human clinical trial, represents a thoughtful attempt to resolve that toxicity problem at the molecular engineering level, and its preclinical data are among the most compelling seen in this […]
HSK46575, a novel CYP11A1 inhibitor designed to suppress the entire steroidogenesis pathway, continues to generate interest in advanced prostate cancer, with new early-phase clinical data providing a clearer picture of its activity and tolerability in patients. At the latest data cut-off, 27 patients with advanced prostate cancer had been treated across dose-escalation cohorts ranging from […]
Early-phase data from the ZL-1310-002 trial introduce a potentially important new therapeutic option for patients with advanced neuroendocrine carcinomas (NECs), a group of aggressive malignancies with very limited treatment options after platinum-based chemotherapy. Among these, neuroendocrine prostate cancer (NEPC) represents one of the most clinically challenging subtypes, characterized by rapid progression, resistance to androgen receptor–targeted […]
ACE‑106 (ACE‑86225106) is a highly selective PARP1 inhibitor designed to improve the therapeutic index compared with first‑generation pan‑PARP inhibitors, which broadly inhibit both PARP1 and PARP2 while causing substantial hematologic toxicity. The updated first‑in‑human data from the open‑label, dose‑escalation study show that ACE‑106 is well tolerated, with no dose‑limiting toxicities, no grade 4–5 treatment‑related adverse […]
225Ac-J591 (Actinium-225 rosopatamab tetraxetan) uses a radioactive particle linked to an antibody that targets PSMA, a protein found on prostate cancer cells, and it is being studied in a phase 1 clinical trial. Unlike more commonly used PSMA treatments that rely on small molecules, this approach uses an antibody, which behaves differently in the body. […]
211AtPSMA-5 emerges as a promising targeted alpha therapy for metastatic castration-resistant prostate cancer, particularly in patients who have exhausted standard treatments like androgen receptor pathway inhibitors, docetaxel, and cabazitaxel. This approach leverages astatine-211, a cyclotron-produced alpha emitter generated by bombarding abundant bismuth targets with alpha beams. The compound’s design mirrors established PSMA ligands such as […]
EXS74539, also called REC-4539, is an experimental cancer drug designed to block LSD1, a protein that helps some cancer cells grow and survive even when standard treatments fail. It is being tested in a phase 1 trial on people with selected solid tumors, including small-cell lung cancer, prostate cancer, ovarian cancer and others. This early-stage […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy